A Patient-Centric Value Framework for Plaque Psoriasis

Plaque psoriasis is a chronic, visible disease that reaches well beyond the skin into a patient's social identity, emotional health, and daily functioning. A qualitative study presented at AAD 2026 identified self-consciousness, anxiety, the felt need to cover affected areas, and strain on personal relationships as the most frequently reported impacts among patients—findings that Francisco Kerdel, MD, FAAD, of Florida Academic Dermatology Center, describes as consistent with what he observes clinically, even if patients do not always volunteer these experiences unprompted. He notes that many patients are reluctant to fully disclose the psychosocial toll of their disease, and that clinicians focused on visible disease metrics may not routinely create space for these conversations.

Among the study's most notable findings: 70% of participants rated total symptom clearance as very important—ranking it higher than speed of response, convenience, or any other treatment attribute. Kerdel reflects that total clearance was always a treatment goal in principle, but for much of dermatology's history it was aspirational rather than achievable. The advent of biologic therapies has made complete clearance a realistic expectation, making it both appropriate and important to make clearance a central part of the conversation with patients. He is mildly surprised that speed of response ranked lower, suggesting that the durability of response may ultimately matter more—patients who achieve full clearance and then experience breakthrough disease are particularly motivated to seek alternatives.

A genuinely useful patient-centric value framework, in Kerdel's view, must incorporate patient preferences around route and frequency of administration—oral versus injectable, frequent versus less frequent dosing—while centering efficacy as the non-negotiable priority. He also emphasizes the reassurance that long-term safety data provide: the absence of cumulative toxicity with newer agents removes a significant barrier to committing to indefinite therapy for a chronic disease.